Vutrisiran Shows Sustained Clinical Benefit in East Asian ATTR-PN Vutrisiran produced consistent improvements in neuropathy impairment, quality of life, walking speed, and disability in patients with ATTR-PN, per a recent study.

East Asian patients with ATTR-PN treated with #Vutrisiran achieve meaningful improvements in neuropathy impairment, quality of life, walking speed, and disability despite higher baseline disease burden and prior #Tafamidis use.

Read more: https://bit.ly/4tgDp38

#RareDisease #ATTRPN #NeuroSky

Tafamidis May Slow the Progression of ATTR-CM Clinical symptoms, serum biomarkers, and imaging parameters worsened substantially after 2 years in patients with ATTR-CM, per a recent study.

Clinical symptoms, serum biomarkers, and imaging parameters worsened substantially after 2 years in patients with transthyretin-mediated amyloid cardiomyopathy (#ATTRCM), whether or not they were treated with #Tafamidis. Study in Clinical Research in Cardiology.

Read more: https://bit.ly/4pun9d5

Real-world #tafamidis treatment improves survival in #ATTR without age affecting efficacy, although mortality remains considerable in octogenarians

#CardioSky
academic.oup.com/eurheartj/ar...
@escardio.bsky.social @barrytrachtenberg.bsky.social @vietheartpa.bsky.social @jimjanuzzi.bsky.social

Multicenter Study of Contemporary Long-Term #Tafamidis Outcomes in #ATTR

#CardioSky #JACCCardioOnc
www.jacc.org/doi/10.1016/...
@jaccjournals.bsky.social @avirupguha.bsky.social @robmentz.bsky.social @jimjanuzzi.bsky.social @venkmurthy.bsky.social @vietheartpa.bsky.social @amyloidosisuk.bsky.social

Transthyretin amyloid #CMP : a paradigm for advancing precision medicine

Advances in knowledge in #transthyretin cardiac #amyloidosis and its specific Rx

#ATTR-CM #HFpEF #tafamidis #diflunisal #acoramidis #CardioEd

academic.oup.com/eurheartj/ad... @escardio.bsky.social @cardioobdoc.bsky.social

Single-photon emission computed tomography/computed tomography quantification of Tc-99m pyrophosphate uptake to assess tafamidis treatment response in transthyretin cardiac amyloidosis Cardiac imaging with bone-avid tracers for the diagnosis of transthyretin amyloid (ATTR) cardiac amyloidosis uses only limited quantification, but single-photon emission computed tomography/computed tomography (SPECT/CT) acquisition can provide volumetric assessment with quantification of tracer uptake. Tafamidis is routinely used in the treatment of cardiac amyloidosis, but there are scant data on changes in imaging results during therapy. The purpose of this study was to perform a longitudinal assessment of Tc-99m-pyrophosphate (PYP) imaging to determine if tafamidis therapy results in any change in quantitative measures of tracer uptake.

SPECT/CT quantification of Tc-99m PYP uptake to assess #tafamidis treatment response in #ATTR

#CardioSky #MedSky #cvNuc
@asnc.bsky.social @edwardmillermd.bsky.social @cesiagallegos.bsky.social @robmentz.bsky.social @anastasiasmihaili.bsky.social
www.journalofnuclearcardiology.org/article/S107...